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Abstract
BACKGROUND: Improved risk stratification of early
colorectal cancer might help to better select patients
for adjuvant treatment. Alterations in the transforming
growth factor-h (TGF-h) pathway have frequently been
found in colorectal cancer, but their impact on
prognosis remains controversial. We therefore ana-
lyzed two transcriptional corepressors of the TGF-h
signaling pathway with respect to prognosis and
prediction of chemotherapy benefit in early colorectal
cancer. METHODS: The gene copy status of SKI and
SNON was analyzed by use of quantitative real-time
polymerase chain reaction in 179 colorectal tumor
biopsies, which had been collected from a randomized
multicenter trial of the Swiss Group for Clinical Cancer
Research (SAKK). RESULTS: Partial or complete allelic
loss was found in 41.5% and 55.2% for SKI and SNON,
whereas amplification was found in 10.1% and 15.1%,
respectively. Multivariate Cox analysis showed that
gene amplification of SKI independently predicted
reduced relapse-free [hazard ratio (HR) for relapse
2.08, P = .049] and overall survival (HR for death 2.62,
P = .012). In contrast, deletion of SKI and the gene copy
status of SNON were not significantly correlated with
prognosis. CONCLUSION: Amplification of SKI is a
negative prognostic marker in early-stage colorectal
cancer. This marker should help to improve risk
stratification to better select patients for adjuvant
therapy. Confirmatory investigations are warranted.
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Introduction
A significant proportion of patients with early-stage colorec-
tal cancer who are undergoing surgical resection with
curative intention eventually relapse and die of metastatic
disease [1]. Recurrence of high-risk tumors has been sig-
nificantly reduced by adjuvant treatment and, thereby, over-
all survival (OS) rates have been improved. The decision to
provide adjuvant treatment is based on a risk assessment,
the mainstay of which is pathologic staging according to the
Dukes system. This system does not take into account recent
advances in our understanding of molecular biology, including
the signal transduction systems in colorectal cancer.
Colorectal cancer has become a prototype malignancy to
describe general principles of molecular carcinogenesis result-
ing from an accumulation of genetic alterations, which lead to
the activation of oncogenes and inactivation of tumor-suppres-
sor genes [2]. Specifically, inactivation of the adenomatous
polyposis coli (APC)/h-catenin pathway, mutation of the k-RAS
gene, deletion of chromosome 17p with the p53 gene, and
loss of chromosome 18q harboring DCC [3] and, more impor-
tantly, transforming growth factor-h (TGF-h) signal-transducing
molecules SMAD2, SMAD4 [4], and SMAD7 [5,6] have been
found. The importance of the TGF-h pathway in colorectal
tumorigenesis has been further demonstrated by the finding
of frequent inactivating mutations of the TGF-h receptor II [7],
SMAD2 [8], SMAD4 [9], and TGF-h itself [10]. It therefore has
been hypothesized that most colorectal cancers have an
alteration in at least one component of the TGF-h signaling
pathway [11].
TGF-h is signaling through heterodimerization of TGF-h
type I and type II receptors, which, in their activated state,
phosphorylate SMAD2 and SMAD3. This phosphorylation
allows the formation of a heterotrimeric complex with SMAD4,
which translocates into the nucleus. This activated SMAD
(MAD, mothers against decapentaplegic, Dresophila, homo-
log) complex will either activate or repress gene expression by
recruiting either coactivators or corepressors [12]. Such co-
repressors are the Sloan-Kettering Institute proto-oncogene
(SKI ) [13] and its relative Ski-related novel gene N (SNON =
skil ) [14]. SKI binds to the nuclear transcriptional corepressors,
N-CoR/SMRT, and the adaptor molecule, mSin3A, forming a
macromolecular complex. Through the adaptor, mSin3A, his-
tone deacetylases are recruited, whose effects generally lead
to chromatin condensation at target gene promoters, thereby
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repressing transcriptional response [15,16] SNON, which is
also a corepressor, interacts with SMAD, and plays a role in
the suppression of SMAD signaling in the absence of TGF-h
and in negative regulation after TGF-h stimulation [14,17].
In fact, these genes might be involved in the dual role
TGF-h is playing during tumorigenesis by induction of cell
cycle arrest in early stages and promotion of proliferation,
angiogenesis, and metastasis in the late stages. We decided
to evaluate the role of SKI and SNON in colorectal cancer. To
this aim, we determined the gene dosage of SKI and SNON
by quantitative real-time polymerase chain reaction (PCR) in
179 tumor samples, which had been collected from a ran-
domized trial of theSwissGroup for Clinical CancerResearch
(SAKK 40/81) by evaluating the effect of 5-FU–based short-
term perioperative chemotherapy in stage II and stage III
colorectal cancer [18]. We determined the prevalence of
gene copy changes and correlated the gene copy status
with prognosis and prediction of chemotherapy benefit.
Patients and Methods
Patients
Paired primary tumor and normal tissue biopsies were
obtained from patients involved in a randomized trial of the
SAKK for the benefit of 5-FU/MMC adjuvant chemotherapy
(SAKK trial 40/81) versus surgery alone. The chemotherapy
consisted of an immediate postoperative infusion with 5-FU
(500 mg/m2) for 7 days, with one single dose of mitomycin
(10 mg/m2) on day 1. The study population comprised 533
patients younger than 75 years, with a median age of 62
years. A total of 63.4% of the patients had colonic carcinoma
and 36.6% had rectal carcinoma. A total of 62.4% was node-
negative (stage II) and 31.1% was node-positive (stage III),
and in 6.5%, the nodal status was not assessed. Details of
this trial have been described previously [1]. From this trial,
179 biopsies from a subpopulation representative of the
whole study population (Table 1) were available for analysis.
The trial was performed after acceptance by the local ethics
committee.
Gene Copy Status
Genomic DNA was extracted from formalin-fixed and
paraffin-embedded tumor and normal tissue biopsies derived
from the same patients using the Nucleospin C + T kit
(Macherey-Nagel, Du¨rren, Germany), according to the man-
ufacturer’s instructions.
The gene copy status of SKI and SNON was established
by gene dosage with real-time quantitative PCR using the
TaqMan system on an ABI PrismR 7700 sequence detector
(Applied Biosystems, Foster City, CA), as described previ-
ously [4]. This technique is based on a two-step process
consisting of PCR amplification and hybridization of an
oligomer fluorescence probe to the PCR target sequence.
During amplification, the probe is digested by the 5V exonu-
clease activity of the Taq DNA polymerase, leading to
separation of the fluorescence dye and its quencher, which
results in an increase in fluorescence emission that is
continuously detected during the amplification process.
The protocol for gene dosage is given in Boulay et al. [19].
In brief, 1 ml of DNA was mixed with 0.5 mM of each primer,
and the labeled probe (0.1 mm) with 12.5 ml of the TaqmanR
Universal PCR Master Mix (Applied Biosystems) in a total
volume of 25 ml. All reactions were performed in triplicate.
Cycling conditions were according to the manufacturer’s
instructions: 50jC for 2 minutes, 95jC for 10 minutes to
activate AmpliTaq GoldR DNA Polymerase (Applied Biosys-
tems), followed by 40 cycles of 95jC for 15 seconds, and











For each individual, the C t value obtained for the autoso-
mal reference gene 36B4 (calculated by the built-in software)
on normal tissue was subtracted from that of tumor tissue,
thus defining DCt 36B4. An analogous calculation was made
for each gene. The gene copy status is indicated by the DC t
value (DC t 36B4 DCt gene) as follows:0.45 < DCt < 0.45,
normal diploidy; DCt< 0.55, deletion; and DC t > 0.55,
amplification.
Statistical Analysis
Each gene status was considered as a categorical vari-
able with three categories: amplification, deletion, and
no change. Two multiple Cox regression models were
Table 1. Patient Characteristics of the 179 Patients.




Sex (number of patients)
Female 55 35 90 (50.2%)
Male 54 35 89 (48.8%)
Involvement of regional lymph nodes (number of patients)
Yes 38 23 61 (34%)
No 64 45 109 (60.8%)
Missing 7 2 9 (5.2%)
Locally advanced tumor (number of patients)
Yes 76 51 127 (70.9%)
No 33 19 52 (29.1%)
Rectal tumor (number of patients)
Yes 34 15 49 (27.3%)
No 75 55 130 (72.7%)
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performed to test the prognostic and predictive values of the
status of SKI andSNON, respectively, on disease-free (DFS)
and overall survival (OS). In addition to treatment arm,
known prognostic factors, namely patients’ age at study
entry, sex, lymph node status, tumor size, and tumor loca-
tion, were included in the regression analysis to control for
their influence. The results are presented with hazard ratio
(HR) and 95% confidence interval. Statistical tests were
carried out at the 5% significance level (two-sided).
For both genes, the interaction between treatment arm
and gene copy status was included in the regression anal-
ysis. The test for prognostic effects was based on the
statistical significance of the parameter estimates for the
terms gene amplification and gene deletion, and the test of
predictive effects on the treatment  amplification and treat-
ment  deletion interaction terms. A significant treat-
ment  amplification interaction would mean that the risk
for patients with amplification relative to patients without
change for a given gene differs between patients with and
without adjuvant chemotherapy. Analogously, it also would
mean that the relative risk of patients with versus without
adjuvant chemotherapy differs between patients with ampli-
fication and those without change. The same logic applies for
the treatment  deletion interaction. Survival curves were
estimated by the Kaplan-Meier method.
Results
We have analyzed 179 paired tumor and normal tissue DNA
samples to establish the gene copy status of SKI and SNON.
Of the 179 samples, 159 and 165 were informative for SKI
and SNON, respectively. A partial or complete allelic loss
was found in 41.5% and 55.2% for SKI and SNON, whereas
an amplification was found in 10.1% and 15.1%, respectively
(Table 2). The molecular analysis was performed blindly for
the clinical outcome data.
The results of the multivariate Cox regressions imply that
SKI amplification is a negative prognostic indicator of DFS
[HR for relapse in patients with amplification relative to those
with no change of gene copy number (= normal diploidy) on
SKI locus: 2.08, P = .049] and OS (HR for death in patients
with amplification relative to those with no change of gene
copy number on SKI locus: 2.62, P = .012) in this population.
Thus, patients carrying a tumor with a SKI amplification had a
two times higher risk of relapse and a 2.6 times higher risk of
death than patients with no change of gene copy number at
the SKI locus (Table 3). A deletion at the SKI locus did not
significantly change the patients’ prognosis (details in
Table 3). Given that patients with SKI deletion were not
significantly different from patients with no change, we
pooled these two groups to form the group of all patients
lacking SKI amplification to be compared to those with
amplification. A Cox regression with the same covariates
as described above was run for each of both outcomes. The
results were consistent with the ones reported above.
Patients bearing SKI amplification had a risk of relapse twice
as high and a risk of death two and a half times higher than
patients bearing no amplification on SKI [for DFS: HR = 2.13,
P = .028; for OS: HR = 2.65, P = .006].
Figure 1 shows the Kaplan-Meier curves for DFS and OS
of patients carrying tumors with SKI amplification compared
to tumors without amplification (normal diploidy and deletion)
ofSKI. As opposed to the amplification of SKI, changes in the
gene copy number of SNON were not significantly associat-
ed with prognosis (Table 3 and Figure 2).
For both SKI and SNON, all interactions between
gene status and treatment arm were not significant with
P values > .2. Therefore, for both SKI and SNON, the risk of
relapse and the risk of death were not significantly different
between patients with and without adjuvant chemotherapy.
Discussion
Pathological analysis of resected tumor specimens is still the
best established method to predict the survival of colorectal
cancer patients [20]. Nevertheless, the clinical outcome of
patients bearing tumors with the same stage is very heter-
ogeneous. To define the prognosis and to plan appropriate
adjuvant treatment, additional predictors are needed. This is
particularly important for patients with stage II disease who
are not routinely treated with adjuvant chemotherapy, and
among whom selection of bad-risk patients who would
significantly benefit from adjuvant treatment would be espe-
cially helpful. Furthermore, with the introduction of more
efficient but also more toxic adjuvant therapy regimens, risk
stratification becomes an issue of even higher relevance.
This study strongly suggests that the gene copy status
of SKI is an independent predictor of relapse-free survival
Table 2. Frequencies of the Gene Markers in 159 Patients Informative for
SKI and 165 Patients Informative for SNON.
Gene Marker Marker Status Number %
SKI No change 77 48.4
Deletion 66 41.5
Amplification 16 10.1
SNON No change 49 29.7
Deletion 91 55.2
Amplification 25 15.1
Table 3. Results of the Multivariate Cox Regressions for DFS and OS.
Marker DFS OS
Relative Risk 95% Confidence Interval P Value Relative Risk 95% Confidence Interval P Value
Deletion versus no change of SKI 0.96 0.56–1.65 0.891 1.01 0.56–1.81 0.984
Amplification versus no change of SKI 2.08 1.00–4.30 0.049 2.62 1.23–5.56 0.012
Deletion versus no change of SNON 1.22 0.70–2.11 0.476 1.42 0.79–2.57 0.242
Amplification versus no change of SNON 1.33 0.66–2.68 0.426 1.72 0.83–3.55 0.145
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and OS in early colorectal cancer. Amplification of SKI was
identified as a negative prognostic marker in stage II and
stage III colorectal cancer, with a risk of relapse twice as
high as for tumors bearing a normal diploidy at the SKI
locus. In the multivariate analysis, this association was
shown to be independent of age, sex, lymph node status,
tumor size, and tumor location, and can therefore be used
as an independent prognostic marker to identify high-risk
situations, thus influencing the decision to provide adjuvant
treatment. Based on our data, patients with stage II
disease and SKI-amplified tumors should be considered
to have a higher risk of relapse, representing a molecularly
defined subgroup that might benefit from adjuvant treat-
ment. However, due to the low rate of SKI amplification
(10.1%), the 95% confidence interval for HR is quite large
and, therefore, a confirmatory investigation in a larger
sample would be important to definitely establish the role
of SKI amplification.
The association of SKI amplification and unfavorable
prognosis implies a causal relation to colorectal tumorigen-
esis. Considering, however, that it affects only 10% of the
tumors, it should not be regarded as a prerequisite but as a
possible lesion in the multistage colorectal tumorigenesis.
This is in line with the findings of other TGF-h signaling
molecules, which are frequently, but not in all cases, altered
in colorectal cancer by point mutation [11] or deletion.
SMAD2, SMAD4, and SMAD7, for example, were found to
be deleted in 66%, 64%, and 48% of the colorectal tumors,
respectively [4]. Of these, SMAD7 has been shown to be a
positive prognostic factor [2], whereas SMAD2 and SMAD4
seem to be unrelated to a prognostic effect. This is in line with
the view that colorectal cancer may harbor defects in the
TGF-h signaling pathway at different levels, influencing
tumor biology and thereby the patient’s prognosis.
Our result of an association between SKI amplification
and worse prognosis is easily explained by several previous
findings. As expected for a proto-oncogene, overexpression
of SKI has been shown to induce morphological transforma-
tion and anchorage independence [13]. Furthermore, it has
Figure 1. Kaplan-Meier plot for DFS and OS for patients bearing tumors with
amplification compared to patients without amplification (normal diploidy and
deletion) at SKI locus. The P values are from the multiple Cox regressions.
Figure 2. Kaplan-Meier plot for DFS for patients bearing tumors with
amplification compared to patients with no change at SNON locus and for
patients with tumors with deletion compared with no change of gene copy
number at SNON locus.
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been demonstrated that overexpression of Ski abrogates not
only transcription of TGF-h–responsive genes, but also
TGF-h–induced growth arrest (i.e., it has a tumor-promoting
potential) [15,16]. In melanoma, SKI has been found not only
in the nucleus but also in the cytoplasm, where it comes to a
SKI/SMAD2/3 association that seems to prevent SMAD3
nuclear translocation in response to TGF-h [21]. A recent
report demonstrated that SKI can block TGF-h signaling by
interfering with the phosphorylation of SMAD2 and SMAD3
by the activated TGF-h type I receptor. In addition, it facili-
tates the assembly of SMAD2/SMAD4 and SMAD3/SMAD4
complexes independent of TGF-h signaling, thereby dis-
abling TGF-h signaling by engaging SMAD proteins in
nonproductive complexes [22]. TGF-h target gene transcrip-
tion, which in early tumor stages results in cell cycle arrest,
can be inhibited by all these mechanisms, thereby explain-
ing the facilitated growth of SKI-amplified tumors. As an
interesting alternative mechanism, in human melanoma
cells, SKI has been shown to be a coactivator of the
Wnt/h-catenin signaling pathway [23]. This pathway has
been well characterized in colorectal cancer and activation
promotes tumorigenesis. Through this mechanism, the
tumor-promoting activity of SKI amplification in colorectal
cancer would be easily explained.
On the contrary, SKI deletion did not have any prognostic
relevance in our analysis. In accordance with our study,
which found SKI deletions in 47% of the samples, loss of
chromosome 1p36, the chromosomal region where SKI is
located, has been reported in several studies at frequencies
between 30% and 80% [24–27]. Two studies reported a
negative prognostic value of 1p36 deletion [28,29]. Our data,
however, do not support a prognostic relevance of 1p36 and
specifically not of SKI. The frequent deletions of SKI in 47%
of colorectal cancers suggest that SKI might act as a tumor-
suppressor gene. In fact, in Ski-deficient heterozygous mice,
an increased susceptibility to tumorigenesis, mainly of lym-
phomas and leukemias, was observed. In that study, how-
ever, no colorectal cancers were observed [30]. This might
be due to interspecies variations in tumor susceptibility, but it
could also mean that SKI deletion is not causally linked to
colorectal carcinogenesis.
SNON, the other member of theSKI gene family, was also
found to be frequently deleted (55% of the tumors) in our
colorectal cancer samples. SNON is located at 3q36, a
region with a high frequency of loss in human osteosarcoma.
In the mouse, SnoN has been demonstrated to act as a
tumor suppressor, but again, there were no colorectal can-
cers observed [31]. This is in line with our data suggesting
SNON gene copy alterations not to be significantly associ-
ated with patients’ prognosis. We have to be careful when
excluding a possible prognostic value of SNON deletion
because our lack of statistical significance might be due to
the relatively low power of our analyses. The statistical power
for SNON deletion (deletion versus no change) was 0.33 in
the DFS analysis and 0.29 in the OS analysis.
Our finding of a lack of significant interaction (P > .2) be-
tween treatment and gene copy status of SKI and SNON is
consistent with the suggestion that the effect of chemother-
apy is not mediated through genes that are regulated by the
interaction of SKI or SNON with the SMAD3 and SMAD4
complex. However, due to the small sample size, the lack of
significance is difficult to interpret because the statistical
power to exclude an interaction is low.
In conclusion, we have identified SKI amplification as an
independent prognostic factor in early-stage colorectal can-
cer. Our finding might become relevant in the current
attempts to improve risk stratification in the decision for or
against an adjuvant treatment regimen.
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